24.03.2023 - ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) - Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with .
ENCINITAS, Calif., March 11, 2023 (GLOBE NEWSWIRE) Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), has learned that Silicon Valley Bank (“SVB”) has been closed by the California Department of Financial Protection and Innov.
– On track to fulfill all elements of Vision 3x3 to build a sustainable, profitable, leading biopharma company COPENHAGEN, Denmark, Jan. 08, 2023 Ascendis Pharma A/S today. | January 8, 2023